[go: up one dir, main page]

PE20050141A1 - DERIVADOS DE 2-ALQUINIL-Y 2-ALQUENIL-PIRAZOLO-[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIDINA COMO ANTAGONISTAS DEL RECEPTOR A2a ADENOSINA - Google Patents

DERIVADOS DE 2-ALQUINIL-Y 2-ALQUENIL-PIRAZOLO-[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIDINA COMO ANTAGONISTAS DEL RECEPTOR A2a ADENOSINA

Info

Publication number
PE20050141A1
PE20050141A1 PE2004000392A PE2004000392A PE20050141A1 PE 20050141 A1 PE20050141 A1 PE 20050141A1 PE 2004000392 A PE2004000392 A PE 2004000392A PE 2004000392 A PE2004000392 A PE 2004000392A PE 20050141 A1 PE20050141 A1 PE 20050141A1
Authority
PE
Peru
Prior art keywords
alkenyl
alkyl
alkinyl
triazolo
antagonists
Prior art date
Application number
PE2004000392A
Other languages
English (en)
Inventor
Jinsong Hao
Hong Liu
Boyle Craig D
Unmesh G Shah
Bernard R Neustadt
Andrew Stamford
Samuel Chackalamannil
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20050141A1 publication Critical patent/PE20050141A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE 2-ALQUINIL-Y 2-ALQUENIL-PIRAZOLO-[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIDINA DE FORMULA I INCLUYENDO SUS SALES FARMACEUTICAMENTE ACEPTABLES, DONDE R ES a; R1, R2, R3, R4 Y R5 SON H, ALQUILO o ALCOXIALQUILO; R6 ES H, ALQUILO, HIDROXIALQUILO o CH2F; R7, R8 Y R9 SON H, ALQUILOALCOXI, ALQUILTIO, ALCOXIALQUILO, HALO o CF3; Z ES R10-ARILO, R10-HETEROARILO, ENTRE OTROS; R10 ES 1-5 SUSTITUYENTES SELECCIONADOS DE H, ALQUILO, ALQUENILO, HIDROXI, ALCOXI, HIDROXIALQUILO, ENTRE OTROS. UN COMPUESTO PREFERIDO ES LA FORMULA II, ENTRE OTROS . TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. ESTOS COMPUESTOS SON ANTAGONISTAS DEL RECEPTOR A2a Y SON UTILES PARA TRATAR ENFERMEDADES DEL SISTEMA NERVIOSO CENTRAL, EN PARTICULAR LA ENFERMEDAD DE PARKINSON
PE2004000392A 2003-04-23 2004-04-21 DERIVADOS DE 2-ALQUINIL-Y 2-ALQUENIL-PIRAZOLO-[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIDINA COMO ANTAGONISTAS DEL RECEPTOR A2a ADENOSINA PE20050141A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46484003P 2003-04-23 2003-04-23

Publications (1)

Publication Number Publication Date
PE20050141A1 true PE20050141A1 (es) 2005-04-01

Family

ID=33310963

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004000392A PE20050141A1 (es) 2003-04-23 2004-04-21 DERIVADOS DE 2-ALQUINIL-Y 2-ALQUENIL-PIRAZOLO-[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIDINA COMO ANTAGONISTAS DEL RECEPTOR A2a ADENOSINA

Country Status (31)

Country Link
US (2) US6897217B2 (es)
EP (1) EP1622912B1 (es)
JP (2) JP4527712B2 (es)
KR (1) KR100831107B1 (es)
CN (1) CN100503609C (es)
AR (1) AR044041A1 (es)
AT (1) ATE432282T1 (es)
AU (1) AU2004233334B2 (es)
BR (1) BRPI0409787B8 (es)
CA (1) CA2522813C (es)
CL (1) CL2004000847A1 (es)
CO (1) CO5700766A2 (es)
CY (1) CY1109263T1 (es)
DE (1) DE602004021250D1 (es)
DK (1) DK1622912T3 (es)
EC (1) ECSP056115A (es)
ES (1) ES2326270T3 (es)
HR (1) HRP20090394T1 (es)
IL (1) IL171567A (es)
MX (1) MXPA05011366A (es)
MY (1) MY139344A (es)
NO (1) NO332182B1 (es)
NZ (1) NZ542823A (es)
PE (1) PE20050141A1 (es)
PL (2) PL1622912T3 (es)
PT (1) PT1622912E (es)
RU (1) RU2373210C2 (es)
SI (1) SI1622912T1 (es)
TW (2) TWI375677B (es)
WO (1) WO2004094431A2 (es)
ZA (1) ZA200508489B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7313588B1 (en) * 2000-07-13 2007-12-25 Biap Systems, Inc. Locally executing software agent for retrieving remote content and method for creation and use of the agent
CA2468649C (en) * 2001-11-30 2009-03-10 Schering Corporation Adenosine a2a receptor antagonists
TWI331036B (en) * 2002-12-19 2010-10-01 Schering Corp Adenosine a2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
US20060128694A1 (en) * 2002-12-19 2006-06-15 Michael Grzelak Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
KR100831107B1 (ko) * 2003-04-23 2008-05-20 쉐링 코포레이션 2-알키닐- 및 2-알케닐-피라졸로-[4,3-ｅ]-1,2,4-트리아졸로-[1,5-ｃ]-피리미딘 아데노신 Ａ2ａ 수용체 길항제 및 이를 포함하는 약제학적 조성물
DE602005020127D1 (de) * 2004-04-21 2010-05-06 Schering Corp Pyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine als antagonisten des adenosin-a2a-rezeptors
EP1902716A4 (en) * 2005-06-07 2009-05-13 Kyowa Hakko Kirin Co Ltd PROPHYLACTIC AND / OR THERAPEUTIC AGENT FOR MOTOR TROUBLESHOOTING
ATE538123T1 (de) 2005-09-19 2012-01-15 Schering Corp 2-heteroarylpyrazoloä4,3-eü-1, 2, 4-triazolo-ä1,5-cü-pyrimidine als antagonisten des adenosin-a2a- rezeptors
AR056080A1 (es) * 2005-09-23 2007-09-19 Schering Corp 7-[2-[4-(6-fluoro-3-metil-1,2-benciosoxazol-5-il)-1-piperazinil]etil]-2-(1-propinil)-7h-pirazol-[4,3-e]-[1,2,4]-triazol-[1,5-c] -pirimidin-5-amine
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
US7691869B2 (en) 2007-03-30 2010-04-06 King Pharmaceuticals Research And Development, Inc. Pyrrolotriazolopyrimidine derivatives, pharmaceutical compositions containing them and methods of treating conditions and diseases mediated by the adenosine A2A receptor activity
JP2011513417A (ja) * 2008-03-04 2011-04-28 シェーリング コーポレイション アデノシンＡ２ａ受容体アンタゴニストとして使用するための１，２，４−トリアゾロ［４，３−ｃ］ピリミジン−３−オンおよびピラゾロ［４，３−ｅ］−１，２，４−トリアゾロ［４，３−ｃ］ピリミジン−３−オン化合物
US8512594B2 (en) * 2008-08-25 2013-08-20 Air Products And Chemicals, Inc. Curing agent of N,N′-dimethyl-meta-xylylenediamine and multifunctional amin(s)
US8501997B2 (en) 2008-08-25 2013-08-06 Air Products And Chemicals, Inc. Curing agent for low temperature cure applications
CN102421767B (zh) 2009-03-10 2014-06-18 武田药品工业株式会社 苯并呋喃衍生物
WO2011017299A2 (en) * 2009-08-07 2011-02-10 Schering Corporation PROCESS FOR PREPARING A 2-ALKYNYL SUBSTITUTED 5-AMINO-PYRAZOLO-[4,3-e]-1,2,4-TRIAZOLO[1,5-c]PYRIMIDINE
US8420661B2 (en) * 2010-04-13 2013-04-16 Hoffmann-La Roche Inc. Arylethynyl derivatives
EP2797878B1 (en) * 2011-12-27 2017-08-16 Bio-Pharm Solutions Co., Ltd. Phenyl carbamate compounds for use in preventing or treating stroke
WO2014101120A1 (en) * 2012-12-28 2014-07-03 Merck Sharp & Dohme Corp. Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
HUE035966T2 (en) * 2013-03-14 2018-05-28 Galapagos Nv Compounds and compositions for the treatment of inflammatory diseases
US11498923B2 (en) 2017-12-13 2022-11-15 Merck Sharp & Dohme Llc Substituted imidazo[1,2-c]quinazolines as A2A antagonists
US20230024108A1 (en) * 2019-07-17 2023-01-26 Teon Therapeutics, Inc. Adenosine a2a receptor antagonists
CN115160120B (zh) * 2022-08-02 2024-08-27 乐威医药（江苏）股份有限公司 一种多烷氧基芳香酮的合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US785906A (en) * 1904-12-06 1905-03-28 Albert P Mcbride Casing packer and shoe for gas or oil wells.
MX16165A (es) * 1988-05-25 1994-02-28 Dow Chemical Co Alcoxi-1,2,4-triazolo[1,5-c]pirimidin-2-sulfonamidas, procedimiento para su preparacion e intermediarios.
IT1264901B1 (it) 1993-06-29 1996-10-17 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina
ATE208199T1 (de) * 1993-07-27 2001-11-15 Kyowa Hakko Kogyo Kk Arzneimittel gegen parkinsonsche krankheit
IT1277392B1 (it) 1995-07-28 1997-11-10 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina
IT1291372B1 (it) 1997-05-21 1999-01-07 Schering Plough S P A Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
DE19826843A1 (de) * 1998-06-16 1999-12-23 Boehringer Ingelheim Pharma Neue Imidazotriazolopyrimidine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
SI1283839T1 (es) * 2000-05-26 2005-08-31 Schering Corp
GB0100624D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
CN1491227A (zh) * 2001-02-05 2004-04-21 株式会社大V制药工厂 三唑并喹唑啉和吡唑并三唑并嘧啶衍生物、医药组合物、腺苷 a 3受体亲和剂、降眼压剂、预防和治疗青光眼的制剂及降低眼压的方法
US6653315B2 (en) 2001-10-15 2003-11-25 Schering Corporation Adenosine A2a receptor antagonists
TWI331036B (en) 2002-12-19 2010-10-01 Schering Corp Adenosine a2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
KR100831107B1 (ko) * 2003-04-23 2008-05-20 쉐링 코포레이션 2-알키닐- 및 2-알케닐-피라졸로-[4,3-ｅ]-1,2,4-트리아졸로-[1,5-ｃ]-피리미딘 아데노신 Ａ2ａ 수용체 길항제 및 이를 포함하는 약제학적 조성물

Also Published As

Publication number Publication date
IL171567A (en) 2013-01-31
AU2004233334B2 (en) 2010-08-12
MXPA05011366A (es) 2005-11-28
EP1622912A2 (en) 2006-02-08
ECSP056115A (es) 2006-03-01
PT1622912E (pt) 2009-08-17
RU2005136166A (ru) 2006-06-10
KR100831107B1 (ko) 2008-05-20
CN100503609C (zh) 2009-06-24
AR044041A1 (es) 2005-08-24
SI1622912T1 (sl) 2009-10-31
HK1085466A1 (en) 2006-08-25
NO20055510L (no) 2006-01-20
AU2004233334A1 (en) 2004-11-04
TWI375677B (en) 2012-11-01
WO2004094431A2 (en) 2004-11-04
ES2326270T3 (es) 2009-10-06
CO5700766A2 (es) 2006-11-30
HRP20090394T1 (hr) 2009-08-31
PL378867A1 (pl) 2006-05-29
NZ542823A (en) 2009-03-31
US6897217B2 (en) 2005-05-24
CL2004000847A1 (es) 2005-03-11
NO20055510D0 (no) 2005-11-22
DK1622912T3 (da) 2009-09-07
US20040220194A1 (en) 2004-11-04
PL1622912T3 (pl) 2009-11-30
TW200427689A (en) 2004-12-16
EP1622912B1 (en) 2009-05-27
DE602004021250D1 (de) 2009-07-09
BRPI0409787B8 (pt) 2021-05-25
ZA200508489B (en) 2007-04-25
CA2522813A1 (en) 2004-11-04
KR20060005379A (ko) 2006-01-17
RU2373210C2 (ru) 2009-11-20
US7368449B2 (en) 2008-05-06
TW201144317A (en) 2011-12-16
CY1109263T1 (el) 2014-07-02
NO332182B1 (no) 2012-07-23
CA2522813C (en) 2009-09-08
JP2010059178A (ja) 2010-03-18
JP2006523619A (ja) 2006-10-19
TWI355381B (en) 2012-01-01
MY139344A (en) 2009-09-30
JP4527712B2 (ja) 2010-08-18
BRPI0409787B1 (pt) 2018-08-21
BRPI0409787A (pt) 2006-05-30
US20050222164A1 (en) 2005-10-06
WO2004094431A3 (en) 2004-12-02
ATE432282T1 (de) 2009-06-15
CN1777609A (zh) 2006-05-24

Similar Documents

Publication Publication Date Title
PE20050141A1 (es) DERIVADOS DE 2-ALQUINIL-Y 2-ALQUENIL-PIRAZOLO-[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIDINA COMO ANTAGONISTAS DEL RECEPTOR A2a ADENOSINA
PE20020911A1 (es) Derivados de indol como agonistas de 5ht2
JP5615902B2 (ja) イミダゾ［２，１−ｂ］［１，３，４］チアジアゾール誘導体
AR036103A1 (es) Imidazotriazinas, procedimiento para su preparacion, uso de dichos compuestos para la manufactura de un medicamento para enfermedades neurodegenerativas y dicho medicamento
UY28578A1 (es) Derivados de amida
AP1860A (en) Aryl fused azapolycyclic compounds.
AR035666A1 (es) Imidazo[4,5-c]quinolin-4-aminas y tetrahidroimidazo[4,5-c]quinolin-4-aminas, composiciones farmaceuticas que las comprenden, uso de dichos compuestos en la preparacion de medicamentos, e intermediarios utiles en la sintesis de dichos compuestos
AR040278A1 (es) Ligandos del receptor de glucocorticoides para el tratamiento de trastornos metabolicos
PE20060185A1 (es) ANTAGONISTA DEL RECEPTOR A2A DE LA ADENOSINA CON ESTRUCTURA DE PIRAZOLO--[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIMIDINA
AR052902A1 (es) Derivados de piridazina, composicion farmaceutica que los contiene y su uso como agentes terapeuticos para enfermedades mediadas por la estearoil-coa desaturasa
PE20040593A1 (es) DERIVADOS DE DIHIDROPIRIMIDO[4,5-d]PIRIMIDONA AMINO SUSTITUIDOS COMO INHIBIDORES DE TIROSINACINASAS DEL GRUPO SRC
MY138352A (en) Benzothiazole derivatives
PE20121511A1 (es) Novedosos derivados biciclicos de triazol sustituidos como moduladores de gamma secretasa
PE20091056A1 (es) PIRIDO[3,2-e]PIRAZINAS, SU PROCEDIMIENTO DE PREPARACION Y USO COMO INHIBIDORES DE FOSFODIESTERASA 10
BRPI0415657A (pt) derivados de alcanamina de diidrobenzofuranila como agonistas de 5ht2c
PE20080182A1 (es) Derivados pirrolo-quinoxalinona como antibacterianos
CY1111032T1 (el) Παραγωγα τετραλινης και ινδανιου και οι χρησεις αυτων
MX2013009627A (es) Derivados de diaminopirimidina y procesos para su preparacion.
AR035945A1 (es) Derivados de piperacina, su uso en la preparacion de medicamentos, procedimiento para la preparacion de dichos compuestos, composiciones farmaceuticas que comprenden dichos compuestos, y metodo para preparar dichas composiciones
PE20060625A1 (es) Derivados de benzazepina como antagonistas y/o agonistas del receptor h3 de histamina
PE20191032A1 (es) Pirido[3,4-b]indoles sustituidos para tratamiento de los trastornos de los cartilagos
PE20040911A1 (es) Derivados de 3h-quinazolin-4-ona como inhibidores selectivos de la monoaminooxidasa b
TW200745130A (en) 2-Heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
PE20060630A1 (es) Amidas sustituidas de acido tienopirrolcarboxilico, amidas del acido pirrolotiazolcarboxilico y analogos relacionados como inhibidores de la caseina cinasa ie
IL174678A0 (en) Arylindenophyridines and arylindenophyrimidines and their use as adenosine a2a receptor antagonist

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed